The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

NCT06022250 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Advanced Malignant Tumor

Interventions

DRUG: JS207

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Collaborators

[object Object]